[go: up one dir, main page]

WO2025158194A1 - A method of preparation of octreotide acetate - Google Patents

A method of preparation of octreotide acetate

Info

Publication number
WO2025158194A1
WO2025158194A1 PCT/IB2024/060906 IB2024060906W WO2025158194A1 WO 2025158194 A1 WO2025158194 A1 WO 2025158194A1 IB 2024060906 W IB2024060906 W IB 2024060906W WO 2025158194 A1 WO2025158194 A1 WO 2025158194A1
Authority
WO
WIPO (PCT)
Prior art keywords
cys
thr
phe
stage
fmoc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/IB2024/060906
Other languages
French (fr)
Inventor
Rakesh SAHAY
Anjan K Roy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Flowchem Pharma Private Ltd
Original Assignee
Flowchem Pharma Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flowchem Pharma Private Ltd filed Critical Flowchem Pharma Private Ltd
Publication of WO2025158194A1 publication Critical patent/WO2025158194A1/en
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Definitions

  • the present invention is in relation to pharmaceutical chemistry.
  • the present invention is in relation to the preparation of Octreotide, in particular to its Acetate salt.
  • the method adopts solid phase synthesis to beget Octreotide Acetate in high yield and purity.
  • Octreotide is an octapeptide of formula A, it has been potentially adopted in the management of various disorders and diseases. It is used in the management of growth hormone related disorders and diseases like Tumours, Acromegaly. Also, the bleeding esophageal varices, and gastrointestinal secretions and fistules are controlled by the use of said compound.
  • Patent document PCT/CA2005/000378 discloses a method of preparation of the Octreotide by a hybrid synthesis wherein the method comprises liquid phase condensation of two or three peptide blocks, of which at least one is synthesized by solid-phase method. Each block contains two or more amino acid residues. The method is cumbersome owing to multiple couplings and purification steps.
  • Patent document PCT/IN2012/000264 adopts liquid phase synthesis for the preparation of the peptide.
  • the linear octapeptide alcohol is treated with cocktail mixture TFA /water/ TIS -9.0:0.5:0.25, to removes the Trt and Boc groups, followed by oxidation with hydrogen peroxide to obtain Octreotide in liquid phase.
  • the present invention provides a method of preparation Octreotide Acetate comprising steps of- a) preparing suitably protected heptapeptide- Cys-Phe-Trp-Lys-Thr-Cys-Thr on a resin by solid phase synthesis, b) oxidizing the heptapeptide to obtain disulphide bridge between the two Cystiene ( Cys) amino acids by solid phase on the resin.
  • Fmoc-Lys-(Boc)-OH(Stage-IV) 4.
  • Fmoc-D-Trp(Boc)-OH(Stage-V) 5.
  • Fmoc-D-Trp(Boc)-OH(Stage-V) 5. Fmoc-Phe-OH(Stage-VI) 6. Fmoc-Cys-Trt-OH(Stage-VII) Trt Trt Fmoc-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-O-Resin Boc Boc tBu tBu (Stage-VII) I 2 / DMF/ MeOH Fmoc-Cys-Phe 4-D-Trp-Lys-Thr-Cys-Thr-O-Resin c.
  • FIG. 1 illustrates mass spectra of the stage VIII compound of the Octreotide Acetate preparation process, with the S-S bridge.
  • Figure 2 illustrates Octreotide HPLC Chromatogram
  • Figure 3 illustrates the Octreotide Acetate HPLC Chromatogram DETAILED DESCRIPTION OF INVENTION
  • the general method of preparation of Octreotide acetate involves the steps of - a) preparing suitably protected heptapeptide- Cys-Phe-Trp-Lys-Thr-Cys-Thr on a resin by solid phase synthesis, b) oxidizing the heptapeptide to obtain disulphide bridge between the two Cystiene ( Cys) amino acids by solid phase on the resin.
  • the resin is 2-Chlorotrityl chloride.
  • the solvent is selected from a group comprising Dichloromethane, N,N'-Diisopropylethylamine, Dimethyl Formamide, Methanol, Water, Acetonitrile, Acetic acid.
  • the protecting group is selected from a group comprising tert-butyloxycarbonyl, 9-Fluorenylmethoxycarbonyl group, Trityl group, N-Hydroxybenzotriazol, tert-butyl group and combination thereof.
  • the Octreotide is purified by High performance liquid chromatography.
  • Fmoc-Thr-(tBu)-O-Resin(Stage-I) In an embodiment of the inv O en c ti r o e n ot t i h d e p A r c o e t t e a c t ted h 1e.p Ftmapoecp-tCys-Trt-OH (Stage-II) 2. Fmoc-Tihdre-( CtByus)--POhHe(-STtrapg-eL-yIIsI)-Thr- 3.
  • Fmoc-Cys-Trt-OH(Stage-VII) 1.
  • Fmoc-Cys-Trt-OH (Stage-II) 2.
  • Acetate Chromatography is Ammonium acetate with Buffer A of 0.5% Acetic acid in water (Stage-XI) and Buffer B with 70% Acetonitrile in Oc Atrceeotitcid aec Aidc.etate The above said method of preparation is depicted in the flowchart -1 below.
  • Example-1 Solid phase synthesis is carried out in 250 ml reactor. Resin 2CTC, 10 gm is charged and swelled with MDC 100 ml for one hr and washed with MDC. Solution of Fmoc- Thr(tBu)-OL (3.0 equivalent) in MDC (1000 ml) and DIEPA ( 5.0 Equivalent) and the resin is kept under stirring for 10 hrs. After reaction, solution is filtered and washed with MDC (100 ml) and DMF (100 ml). End capping is performed with MDC (100 ml) and MeOH (2 ml) with stirring one hr.
  • Example-2 De protection and Coupling Stage 1 resin (13 gm ) is added to DMF ( 130 ml ) and charged to reactor. Deportation is carried using DMF-Piperidine 20% (150 ml) stirring 20 min. Deprotection is confirmed by Kiser test. Reaction mass is washed with DMF (260 ml ) X 5times. Coupling reaction is carried out using Fmoc-Cys-Trt-OH (three equivalent), HOBT (three equivalent) and DIC (5.0 equivalent) in DMF 130 ml. Coupling reaction is confirmed by Kiser test after three hours.
  • Example-3 Stage –III to Stage VII De protection and coupling stages are carried out same as example -2 by respective Fmoc-amino acid in the sequential order- Fmoc- Thr(tBu)-OH, Fmoc-Lys(Boc)-OH, Fmoc-D-Trp(Boc)-OH, Fmoc-Phe-OH, Fmoc-Cys-Trt-OH.
  • Example-4 Stage –VIII To product of stage VII, a solution of Iodine 4 gm in DMF 100 ml and MeOH 100 ml is added. The reaction mass stirred for 4 hrs at room temperature.
  • stage VIII compound Example-5 Stage-IX
  • the above stage VIII product is deprotected by DMF-Piperidine 20% (150 ml) stirring for 30 min which is confirmed by Keiser test. Reaction mas is washed with DMF 250 ml. A solution of Fmoc D-Phe-OH (Three equivalent) in DMF (100ml ) DIC ( Five equivalent ) HOBT (Three equivalent ) is added and stirred for four hrs. Coupling reaction is confirmed by kisers test. Another de protection is carried out by DMF- Piperidine 20% ( 150 ml) stirring for 30 min which is confirmed by Keiser test.
  • Example-6 Stage-X Stage IX ( 18 gm) is charged to RB Flask and TFA (100 ml) is added. The mass is stirred for 4 hrs at room temperature. Solid mass is filtered off and washed with TFA 50 ml. Combined filtrate is distilled under high vacuum below 30 o C. Trace of TFA distilled out by adding 50 ml Toluene. To this mass, MTEB (200 ml) is added and stirred for 2 hrs at RT. The off- white crystals are filtered, washed with MTEB 50 ml.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention is in relation to a method of preparation of Octreotide, in particular to its Acetate salt. The method adopts unique steps along with solid phase synthesis to beget Octreotide Acetate in high yield and purity.

Description

TITLE: A METHOD OF PREPARATION OF OCTREOTIDE ACETATE TECHNICAL FIELD The present invention is in relation to pharmaceutical chemistry. In particular, the present invention is in relation to the preparation of Octreotide, in particular to its Acetate salt. The method adopts solid phase synthesis to beget Octreotide Acetate in high yield and purity. BACKGROUND OF INVENTION Octreotide is an octapeptide of formula A, it has been potentially adopted in the management of various disorders and diseases. It is used in the management of growth hormone related disorders and diseases like Tumours, Acromegaly. Also, the bleeding esophageal varices, and gastrointestinal secretions and fistules are controlled by the use of said compound. It has also been adopted in radiolabelling techniques in the identification of tumours. Mol. Wt.: 101 F9o.2r3m9ula A The importance of Octreotide in medical domain has necessitated to develop simple and cost effective method for large scale production. The patent document US 6,346,601 demonstrates a method of preparation of Octreotide and its salts based on solid phase synthesis. The disclosed method is not suitable for large scale preparation. The patent document PCT/IN2003/00160 discloses a method of preparation of the Octreotide by solution phase peptide chemistry. The method involves condensation of dipeptides and use of reducing agents like sodium borohydride rendering the process to be expensive and unsuitable for large scale synthesis. The patent document PCT/CA2005/000378 discloses a method of preparation of the Octreotide by a hybrid synthesis wherein the method comprises liquid phase condensation of two or three peptide blocks, of which at least one is synthesized by solid-phase method. Each block contains two or more amino acid residues. The method is cumbersome owing to multiple couplings and purification steps. Patent document PCT/IN2012/000264 adopts liquid phase synthesis for the preparation of the peptide. The linear octapeptide alcohol is treated with cocktail mixture TFA /water/ TIS -9.0:0.5:0.25, to removes the Trt and Boc groups, followed by oxidation with hydrogen peroxide to obtain Octreotide in liquid phase. Another document PCT/IN2012/000652 discloses a method of preparation of Octreotide by solid phase synthesis adopting 2-chloritrityl chloride resin by coupling appropriately protected amino acid, deprotection oxidation of the thiol to disulphide followed by purification. The prior art processes require multiple purification steps and expensive reagents due to the steps adopted. The low yield is another disadvantage associated with the processes. It is necessary to develop a method involving fewer steps, high yield and purity, considering the importance of Octreotide in the medical field. SUMMARY OF INVENTION Accordingly, the present invention provides a method of preparation Octreotide Acetate comprising steps of- a) preparing suitably protected heptapeptide- Cys-Phe-Trp-Lys-Thr-Cys-Thr on a resin by solid phase synthesis, b) oxidizing the heptapeptide to obtain disulphide bridge between the two Cystiene ( Cys) amino acids by solid phase on the resin. c) adding the protected amino acid Phenylalanine (Phe) to the heptapeptide and deprotecting the heptapeptide to obtain the Octreotide, Octreotide Acetate d) isolating the Octreotide from the resin and filtering to obtain crude Octreotide, and 2CTC-Resin Fmoc-Thr-(tBu-)-OL e) purifying and lyophilizing to Oc otbretaoitnid Oec Atrce F eotm atito dec e-T Ah cr e-( tt aB teu .)-O-Resin(Stage-I) A 2C mTeCt-hRoeds of prep Famraotico-Tnh Or-c(t Breuo-t)i-dOeL Acetate comp 1r.i Fsimngoc s-tCepyss- oTfr-t-OH (Stage-II) in Fmoc-Th 2.r- F(tmBouc)--OTh-Rr-e(stBinu()S-OtaHg(eS-It)age-III) 3. Fmoc-Lys-(Boc)-OH(Stage-IV) a. preparing protected heptapeptide of formula B 4 o.n Fm 2-oCch-Dlo-Trorptr(iBtyolc c)-hOloHr(iSdteag rees-iVn) 15.. Fmoc --CPhyse--TOrHt-(OSHtag (Set-aVgI)e-II) 26.. Fmoc --TChyrs--(TtBrtu-O)-OH(HS(tSatgage-III) by solid phase synthesis, e-VII) 3. Fmoc-Lys-(Boc)-OH(Stage-IV) 4. Fmoc-D-Trp(Boc)-OH(Stage-V) 5. Fmoc-Phe Trt Tr -OH(Stage-VI) 6. Ftmoc-Cys-Trt-OH(Stage-VII) Fmoc-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-O-Resin Trt Trt Boc Boc tBu tBu Fmoc-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-O-Resin (Stage-VII) Formula B Boc IB 2o /c DMtBF/u MeOH tBu b. oxidizing the heptapeptide of f (oSrtmaguel-aV BII) with Iodine to obtain compound of formula C with Fm disoucl-phideP brhiedg-De- betw I2e /e DnM thTFeh/ t Mrw-eCoOy CHsy-sTthiern-Oe (-CRyess)in amino acids, Boc Boc tBu tBu Fmoc-Cys-Phe-D (-STtrapg-eL-VysIII-)Thr-Cys-Thr-O-Resin Boc Boc FmtBouc-D-Phe t-BOuH (Stage-VIII) D-Phe Formula C Cys-Phe-D-Trp-Lys-T Fhmr-oCcy-Ds--PThher--OOH-Resin Boc Cys-Phe-D-Trp-B Lo yc tBu D-Phe s-Thr-Cys-T t hB ru -O-Resin (Stage-IX) Boc Boc tBu tBu TFA (Stage-IX) D-Phe-Cys-Phe-D-Trp-L TyFsA-Thr-Cys-Thr-OL (Stage-X) D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-OL Acetic Acid (Stage-X) D-Phe-Cys-Phe-D-Trp-L Aysce-Ttihcr A-Cciyds-Thr-OL. Acetate (Stage-XI) D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-OL. Acetate Octreotide Acetate (Stage-XI) Octreotide Acetate Octreotide Acetate 2CTC-Resin Fmoc-Thr-(tBu-)-OL Fmoc-Thr-(tBu)-O-Resin(Stage-I) 1. Fmoc-Cys-Trt-OH (Stage-II) 2. Fmoc-Thr-(tBu)-OH(Stage-III) 3. Fmoc-Lys-(Boc)-OH(Stage-IV) 4. Fmoc-D-Trp(Boc)-OH(Stage-V) 5. Fmoc-Phe-OH(Stage-VI) 6. Fmoc-Cys-Trt-OH(Stage-VII) Trt Trt Fmoc-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-O-Resin Boc Boc tBu tBu (Stage-VII) I2 / DMF/ MeOH Fmoc-Cys-Phe 4-D-Trp-Lys-Thr-Cys-Thr-O-Resin c. adding Fmoc protected amino acBidoc PhBeonyclatlBanuine (Ph teB)u to the compound of (Stage-VIII) formula C obtain compound of formula D F;moc-D-Phe-OH D-Phe Cys-Phe-D-Trp-Lys- Thr-O-Resin Boc Boc tBu tBu (Stage-IX) Formula D TFA d. deprotecting the heptapeptide of formula D to obtain the Octreotide, e. isolating the O Dc-tPrehoeti-dCey fsr-oPmhe th-De r-eTsripn- aLnyds- fTilhterr-iCngys to-T ohbrt-aOinL crude Octreotide, and (Stage-X) f. purifying and lyophilizing to obtain Oc Atrceeottiicde Ac Aidcetate. D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-OL. Acetate A peptide of formula E, (Stage-XI) Formula E BRIEF DESCRIPTION OF FIGURES The features of the present invention can be understood in detail with the aid of appended figures. It is to be noted however, that the appended figures illustrate only typical embodiments of invention and are therefore not to be considered limiting of its scope for the invention. Figure 1: illustrates mass spectra of the stage VIII compound of the Octreotide Acetate preparation process, with the S-S bridge. Figure 2: illustrates Octreotide HPLC Chromatogram Figure 3: illustrates the Octreotide Acetate HPLC Chromatogram DETAILED DESCRIPTION OF INVENTION The foregoing description of the embodiments of the invention has been presented for the purpose of illustration. It is not intended to be exhaustive or to limit the invention to the precise form disclosed as many modifications and variations are possible in light of this disclosure for a person skilled in the art in view of the figures, description and claims. It may further be noted that as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural reference unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by person skilled in the art. Abbreviations: MDC Dichloromethane DIEPA N,N'-Diisopropylethylamine MeOH Methanol Fmoc 9-Fluorenylmethoxycarbonyl Trt Trityl HOBT N-Hydroxybenzotriazol t-Bu tert-butyl TFA Trifluoro Acetic acid MTEB Methyl tert-butyl ether DMF N,N-Dimethylformamide HPLC High-performance liquid chromatography DIC Diisopropylcarbodiimide Lc-Ms Liquid chromatography–mass spectrometry Cys L-Cysteine Boc tert-butoxycarbonyl RT Room Temperature ranging from 20℃ to 35℃ USP US Pharmacopeia The present invention is related to an economical and simple method of preparation of Octreotide and its salt. In particular to a method of preparation of Octreotide acetate by solid phase synthesis. The method yields Octreotide acetate of 99.9% purity. The general method of preparation of Octreotide acetate involves the steps of - a) preparing suitably protected heptapeptide- Cys-Phe-Trp-Lys-Thr-Cys-Thr on a resin by solid phase synthesis, b) oxidizing the heptapeptide to obtain disulphide bridge between the two Cystiene ( Cys) amino acids by solid phase on the resin. c) adding the protected amino acid Phenylalanine (Phe) to the heptapeptide and deprotecting the heptapeptide to obtain the Octreotide, d) isolating the Octreotide from the resin and filtering to obtain crude Octreotide, and e) purifying and lyophilizing to obtain Octreotide Acetate. In an embodiment of the present invention the resin is 2-Chlorotrityl chloride. In another embodiment of present invention, the solvent is selected from a group comprising Dichloromethane, N,N'-Diisopropylethylamine, Dimethyl Formamide, Methanol, Water, Acetonitrile, Acetic acid. In another embodiment of present invention, the protecting group is selected from a group comprising tert-butyloxycarbonyl, 9-Fluorenylmethoxycarbonyl group, Trityl group, N-Hydroxybenzotriazol, tert-butyl group and combination thereof. In an embodiment of present invention the Octreotide is purified by High performance liquid chromatography. Octreotide Acetate 2CTC-Resin Fmoc-Thr-(tBu-)-OL 7 Fmoc-Thr-(tBu)-O-Resin(Stage-I) In an embodiment of the inv Oencti roenot tihde p Arcoetteactted h 1e.p Ftmapoecp-tCys-Trt-OH (Stage-II) 2. Fmoc-Tihdre-( CtByus)--POhHe(-STtrapg-eL-yIIsI)-Thr- 3. Fmoc-Lys-(Boc)-OH(Stage-IV) C 2yCsT-CT-hRre fsoinrmed o Fnm tohce-T rehsri-n(tB isu o-)f-O foLrmula F Bmoc-Th 4. Fmoc-D-Trp(Boc)-OH(Stage-V) 5r.- F(tmBouc)--OP-hRee-OsiHn((SSttaaggee--IV)I) 6. Fmoc-Cys-Trt-OH(Stage-VII) 1. Fmoc-Cys-Trt-OH (Stage-II) 2. Fmoc-Thr-(tBu)-OH(Stage-III) 3 T.r Ftmoc-Lys-(Boc)-OH(Stage-IV) (Boc)-OH(Stage-V) Fmoc- OH(Stage-VI) -TRret-sOinH(Stage-VII) Trt Trt (Stage-VII) Formula B Fmoc-Cys-Phe-D-Trp-L I2y /s D-MThF/r- MCeyOsH-Thr-O-Resin In another embodiment of present invention, the protected peptide of formula B is Boc Boc tBu tBu oxidized to form F dmisoulcp-hCidyes- bPrhideg- (DeS-t bTaygrpe I--oVLdIyIi)nse-T ihnr- aC syosl-vTehnrt-O to-R obetsaiinn compound of formula C. Boc I2B /o DcMFtB/ MueOH tBu (Stage-VIII) Fmoc-C --CDy-Psh-Te-hOrH-O-Resin Boc Boc tBu tBu D-Phe Cys-Phe-D-T (rSpt-aLgyes-V-TIIhI)r-Cys-Thr-O-Resin Formula Boc Fm Coc-D-P th Be u-OH Boc tBu In still another embodiment of present invention, the peptide of formula-E obtained by (Stage-IX) D-Phe Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-O-Resin cleaving compound of formula C from the res TinF.A tBu tBu Thr-OL Thr-OL Thr-OL. Acetate (Stag Aec-eXtIi)c Acid Form Ouclatr-e Eotide Acetate D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-OL. Acetate (Stage-XI) Octreotide Acetate Octreotide Acetate 2CTC-Resin Fmoc-Thr-(tBu-)-OL Fmoc-Thr-(tBu)-O-Resin(Stage-I) 1. Fmoc-Cys-Trt-OH (Stage-II) 2. Fmoc-Thr-(tBu)-OH(Stage-III) 3. Fmoc-Lys-(Boc)-OH(Stage-IV) 4. Fmoc-D-Trp(Boc)-OH(Stage-V) 5. Fmoc-Phe-OH(Stage-VI) 6. Fmoc-Cys-Trt-OH(Stage-VII) Trt Trt Fmoc-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-O-Resin Boc Boc tBu tBu (Stage-VII) I2 / DMF/ MeOH 8 In still another emb Fomdiomce-nCty osf- pPrhesee-nDt- iTnrvpe-nLtyiosn-T, thhre-C pryost-eTctherd-O am-Rineosi ancid Phenylalanine (Phe) is linked to the coBmopcouBnodc oftB fourmula C tB tuo obtain the protected (Stage-VIII) octapeptide of formula D. Fmoc-D-Phe-OH D-Phe Cys-Phe-D-Trp-Lys- Thr-O-Resin Boc Boc tBu tBu Octreo (Stidtaeg Ae-cIXet)ate Formula D 2CTC-Resin Fmoc-Thr-(tBu-)-OL TFA In an embodiment of the presen Otc itnrveoentitdioen A,c t F ehtm eato mec e-T thh or d-(t oB fu p)- rO ep-R ae ras ti in o( nSt oa fge O-I c) treotide aceta 2tCeT iCnv-Roelvseins t Dhe-P s Fhtemep-osCc o-yTfs-h-rP-(htBeu-D-)--OTrLp-Lys-Thr-C 1y.s F-Tmhorc--OCLys-Trt-OH (Stage-II) Fmoc-Th 2.r- F(tmBouc)--OTh-Rr-e(stBinu()S-OtaHg(eS-It)age-III) 3. Fmoc-Lys-(Boc)-OH(Stage-IV) a) preparing protected heptapeptide of (S fotargmeu-Xla) B on 4. Fmoc-D-Trp(Boc)-OH(Stage-V) 12 .-Chlor Cot yr sity Tl OrHt c -h (Ol SHor tag (i Sd ete resin by 5. Fmoc-Phe- -aVgI)e-II) Aceti 26.. Fmoc --TChyrs--(TtBrtu-O)-OH(HS(tSatgaeg-eV-IIII)I) solid phase synthesis, c Acid 3. Fmoc-Lys-(Boc)-OH(Stage-IV) 4. Fmoc-D-Trp(Boc)-OH(Stage-V) 5. Fmoc-Phe-OH(Stage-VI) D-Phe-Cys T-rPthe-D-Trp-Lys-Thr-Cy 6 T s.r - Ft Tmhor-cO-CLy.s A-Tcret-tOaHte(Stage-VII) Fmoc-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-O-Resin (Stage-XI) Trt Trt Octreo Btiodce ABcoectateBu tBu Fmoc-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-O-Resin (Stage-VII) Formual B Boc IB 2o /c DMtBF/u MeOH tBu b) oxidizing the heptapeptide with Io (dSitnaege t-oVI oI)btain disulphide bridge between the two Cystiene ( Cy Fs)m aomci-nCoy asc-iPdhs,e-D-Trp I-2L /y DsM-TFh/ Mr-eCOyHs-Thr-O-Resin Fmoc- Resin Boc Boc FmtBouc-D-Phe t-BOuH (Stage-VIII) D-Phe Formula C Cys-Phe-D-Trp-Lys-T Fhmr-oCcy-Ds--PThher--OOH-Resin Boc D-Phe Cys-Phe-D-Trp-B Lo yc tBu s-Thr-Cys-T t hB ru -O-Resin c) adding the protected amino acid Phenylalanine (Phe) to compound of formula C (Stage-IX) obtain compound of formula D; Boc Boc tBu tBu TFA (Stage-IX) D-Phe-Cys-Phe-D-Trp-L TyFsA-Thr-Cys-Thr-OL (Stage-X) D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-OL Acetic Acid (Stage-X) D-Phe-Cys-Phe-D-Trp-L Aysce-Ttihcr A-Cciyds-Thr-OL. Acetate (Stage-XI) D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-OL. Acetate Octreotide Acetate (Stage-XI) Octreotide Acetate Octreotide Acetate 2CTC-Resin Fmoc-Thr-(tBu-)-OL Fmoc-Thr-(tBu)-O-Resin(Stage-I) 1. Fmoc-Cys-Trt-OH (Stage-II) 2. Fmoc-Thr-(tBu)-OH(Stage-III) 3. Fmoc-Lys-(Boc)-OH(Stage-IV) 4. Fmoc-D-Trp(Boc)-OH(Stage-V) 5. Fmoc-Phe-OH(Stage-VI) 6. Fmoc-Cys-Trt-OH(Stage-VII) Trt Trt Fmoc-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-O-Resin Boc Boc tBu tBu (Stage-VII) I2 / DMF/ MeOH Fmoc-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-O-Resin 9 Boc Boc tBu tBu (Stage-VIII) Fmoc-D-Phe-OH D-Phe Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-O-Resin Boc Boc tBu tBu (Stage-IX) Formula D TFA d) deprotecting the h De-pPtahpee-pCtiydse-P ofhe fo-rDm-Turlap- DLy tos- oTbhtar-inCy thse-T Ohcrt-rOeoLtide, e) isolating the Octreotide from the resin an (Sdta figltee-rXi)ng to obtain crude Octreotide, and f) purifying and lyophilizing to obtain Octreo Aticdeeti Acc Aectaidte. In an embodiment of present invention the eluent in the High Performance Liquid D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-OL. Acetate Chromatography is Ammonium acetate with Buffer A of 0.5% Acetic acid in water (Stage-XI) and Buffer B with 70% Acetonitrile in Oc Atrceeotitcid aec Aidc.etate The above said method of preparation is depicted in the flowchart -1 below.
Octreotide Acetate CTC-Resin Fmoc-Thr-(tBu-)-OL Fmoc-Thr-(tBu)-O-Resin(Stage-I) 1. Fmoc-Cys-Trt-OH (Stage-II) 2. Fmoc-Thr-(tBu)-OH(Stage-III) 3. Fmoc-Lys-(Boc)-OH(Stage-IV) 4. Fmoc-D-Trp(Boc)-OH(Stage-V) 5. Fmoc-Phe-OH(Stage-VI) 6. Fmoc-Cys-Trt-OH(Stage-VII) Trt Trt Fmoc- Resin (Stage-VII) I2 / DMF/ MeOH Fmoc-C -Cys-Thr-O-Resin Boc Boc tBu tBu Fmoc-D-Phe-OH D-Phe Cys-Phe-D-Trp-Lys- Thr-O-Resin Boc Boc tBu tBu (Stage-IX) TFA D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-OL (Stage-X) Acetic Acid D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-OL. Acetate (Stage-XI) Octreotide Acetate FLOWCHART-1 Experimentation: Example-1 Stage 1: Solid phase synthesis is carried out in 250 ml reactor. Resin 2CTC, 10 gm is charged and swelled with MDC 100 ml for one hr and washed with MDC. Solution of Fmoc- Thr(tBu)-OL (3.0 equivalent) in MDC (1000 ml) and DIEPA ( 5.0 Equivalent) and the resin is kept under stirring for 10 hrs. After reaction, solution is filtered and washed with MDC (100 ml) and DMF (100 ml). End capping is performed with MDC (100 ml) and MeOH (2 ml) with stirring one hr. Solid resin is filtered, washed with DMF 200 ml X5. Dry weight of resin is 13 gm. Example-2 De protection and Coupling Stage 1 resin (13 gm ) is added to DMF ( 130 ml ) and charged to reactor. Deportation is carried using DMF-Piperidine 20% (150 ml) stirring 20 min. Deprotection is confirmed by Kiser test. Reaction mass is washed with DMF (260 ml ) X 5times. Coupling reaction is carried out using Fmoc-Cys-Trt-OH (three equivalent), HOBT (three equivalent) and DIC (5.0 equivalent) in DMF 130 ml. Coupling reaction is confirmed by Kiser test after three hours. Reaction mass is filtered and washed with DMF 260ml. Example-3 Stage –III to Stage VII De protection and coupling stages are carried out same as example -2 by respective Fmoc-amino acid in the sequential order- Fmoc- Thr(tBu)-OH, Fmoc-Lys(Boc)-OH, Fmoc-D-Trp(Boc)-OH, Fmoc-Phe-OH, Fmoc-Cys-Trt-OH. Example-4 Stage –VIII To product of stage VII, a solution of Iodine 4 gm in DMF 100 ml and MeOH 100 ml is added. The reaction mass stirred for 4 hrs at room temperature. Solid bed is filtered washed with DMF X 5(100ml each time), MeOH 100 ml, MDC 100 ml. Disulphide Bridge is confirmed by LC-Ms and Ellman’s test. Also, the product is analysed by mass spectra. Approximately, 100 mg, of compound is taken and cleaved the resin by TFA (20 ml), followed by crystallisation with MTEB. Dry product ( compound of formula E) is analysed by Mass spectra. Mass spectral analysis is carried out with Liquid chromatography–mass spectrometer, Shimadzu Lc- Ms 8045. The major peak with mass –to-charge ratio is 1094 M+/M- ( figure 1). Formula -E (Stage VIII compound) Example-5 Stage-IX The above stage VIII product is deprotected by DMF-Piperidine 20% (150 ml) stirring for 30 min which is confirmed by Keiser test. Reaction mas is washed with DMF 250 ml. A solution of Fmoc D-Phe-OH (Three equivalent) in DMF (100ml ) DIC ( Five equivalent ) HOBT (Three equivalent ) is added and stirred for four hrs. Coupling reaction is confirmed by kisers test. Another de protection is carried out by DMF- Piperidine 20% ( 150 ml) stirring for 30 min which is confirmed by Keiser test. Solid bed is filtered and washed with DMF 100 ml and MDC 100 ml. Unloaded solid resin weight is 18 gm. Example-6 Stage-X Stage IX ( 18 gm) is charged to RB Flask and TFA (100 ml) is added. The mass is stirred for 4 hrs at room temperature. Solid mass is filtered off and washed with TFA 50 ml. Combined filtrate is distilled under high vacuum below 30o C. Trace of TFA distilled out by adding 50 ml Toluene. To this mass, MTEB (200 ml) is added and stirred for 2 hrs at RT. The off- white crystals are filtered, washed with MTEB 50 ml. Crude Octreotide obtained, which is dried under vacuum, dry weight 6.0 gm crude (HPLC purity 78%; Figure 2) Example-7 Purification by Preparative HPLC Preparative HPLC is carried out in Knaur Azura Prep HPLC equipment. Octreotide crude (2 gm), is dissolved in 30 ml water loaded in Prep HPLC, using 50 mm C18- 10 µ column. Column bed is saturated with Ammonium Acetate 3%. Buffer A: 0.5% Acetic acid in water with solution in water. Buffer B: 70% Acetonitrile in 0.5% Acetic acid is passed by gradient at 30 ml/ min flow rate gradient (A:B::90:10, 80:20, 70:30.70:30, 40:60, 10:90 ) at 210 nm wavelength. Fractions are collected and lyophilised to get dry pure Octreotide Acetate (800 mg) with HPLC purity 99.90% ( Figure 3). The Specific Optical Rotation of the Octreotide Acetate is analysed by with Rudolph Autopol II and the same is observed to be [α] d20 (C= 2 inMeOH) - 14.850. The amino acid analysis of the Octreotide Acetate carried out with Amino acid analyser SYKAM S433 is indicated in the Table 1. Table 1: Amino acid analysis of Octreotide Acetate SN Name Nmol Result Acceptance (USP Reference) 1 2 3 4 5 6 Thus the present invention provides an economical and facile method of preparation of Octreotide acetate. The other advantages of the invention involves– 1. Formation of Disulphide SS bridge is carried out in solid phase with Trityl / Trityl cysteine (2-7 sequence) without cleavage of resin which results clean process and better purity. In the said step, cleavage of trityl moiety and SS bridging are taking place in one step (insitu). 2. Purification of crude Octreotide is achieved up to 99.9% Octreotide acetate with high yield in single run by prep HPLC. Developed gradient run flow is cost effective and time saving process. 3. The new peptide fragment Fmoc-Cys-Phe-D-(Boc)Trp-(Boc)Lys-(tBu)Thr- Cys-(tBu)-Thr-Resin (Disulfide bridge Cys 2-Cys 7) is separately synthesised and coupled with Fmoc-D-Phe-OH on solid phase followed by global de protection and cleavage of resin. The method retains desired chirality and avoid racemisation of final compound- Octreotide.

Claims

WE CLAIM 1. A method of preparation Octreotide Acetate comprising steps of- a) preparing suitably protected heptapeptide- Cys-Phe-Trp-Lys-Thr-Cys-Thr on a resin by solid phase synthesis, b) oxidizing the heptapeptide to obtain disulphide bridge between the two Cystiene (Cys) amino acids by solid phase on the resin. c) adding the protected amino acid Phenylalanine (Phe) to the heptapeptide and deprotecting the heptapeptide to obtain the Octreotide, d) isolating the Octreotide from the resin and filtering to obtain crude Octreotide, and e) purifying and lyophilizing to obtain Octreotide Acetate. 2. The method of preparation as claimed in claim 1, wherein the resin is 2- Chlorotrityl chloride. 3. The method of preparation as claimed in claim 1, wherein the solvent is selected from a group comprising Dichloromethane, N,N'-Diisopropylethylamine, Dimethyl Formamide, Methanol, Water, Acetonitrile, Acetic acid and combination thereof. 4. The method of preparation as claimed in claim 1, wherein the protecting group is selected from a group comprising tert-butyloxycarbonyl, 9- Fluorenylmethoxycarbonyl group, Trityl group, N-Hydroxybenzotriazol, tert- butyl group and combination thereof. 5. The method of preparation as claimed in claim 1, wherein the heptapeptide is oxidized with Iodine. 6. The method of preparation as claimed in claim 1, wherein the Octreotide is purified by High performance liquid chromatography. Octreotide Acetate 2CTC-Resin Fmoc-Thr-(tBu-)- 1O6L Octreotide Ac F etm ato ec-Thr-(tBu)-O-Resin(Stage-I) 7. A 2C mTeCt-hRoedsi onf prep Famraotico-Tnh Or-c(t Breuo-t)i-dOeL Aceta 1. Fmoc-Cys-Trt-OH (Stage-II) Ftem coocm-Tph 2r.ri-s F(itmnBgouc) s--tOTeh-pRrs-e( ostfBi-nu()S-OtaHg(eS-It)age-III) 3. Fmoc-Lys-(Boc)-OH(Stage-IV) a. preparing protected hepta Opcetpretiodteid oef A focremtautela B 4 1 o.n Fm 2-oCch-Dlo-Trorptr(iBtyolc c)-hOloHr(iSdteag rees-iVn) 5.. Fmoc- CPhyse- TOrHt-(OSHtag (Set-aVgI)e-II) 26.. Fmoc --TChyrs--(TtBrtu-O)-OH(HS(Stage-III) by solid phase Fm syonthesis, tage-VII) 2CTC-Resin c-Thr-(tBu-)-OL Fmoc-Th 3.r- F(tmBouc-Lys-(Boc)-OH(Stage-IV) 4. Fmoc)--OD--RTerps(iBn(oSct)a-gOeH-I()Stage-V) 5. Fmoc-Phe-OH(Stage-VI) Trt -TTrrtt--OOHH( (SSttaaggee--VIII)I) (tBu)-OH(Stage-III) Fmoc- (RBeosci)n-OH(Stage-IV) (Boc)-OH(Stage-V) Boc OH(Stage-VI) Trt-OH(Stage-VII) Fmoc-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-O-Resin (Stage-VII) Formula B Boc Trt IB 2o /c DMtBF/u M TertOH tBu b. oxidizing the heptapeptide of f (oSrtmaguel-aV BI with Iodine to obtain compound of Fmoc-Cys-Phe-D-Trp-LysI)-Thr-Cys-Thr-O-Resin formula C with Fm disoucl-pChyidse-P brhiedg-De- betw Ieen the two Cystiene (Cys) amin B2 / DMF/ MeOH o acids, BoTcrp-Loycs-tTBhur-Cys- tTBhur-O-Resin (St VII) tBu Fmoc-C g -Cys-Thr-O-Resin I2 / DMF/ MeOH Boc Boc FmtBouc-D-Phe t-BOuH (Stage-VIII) Fmoc-Cys-Phe F-oDrm-Turp-Lys-Thr-Cys-Thr-O-Resin D-Phe la C Cys-Phe-D-Trp-Lys-T Fhmr-oCcy-Ds--PThher--OOH-Resin c. adding Fmoc protected amino acBidoc PhBeonyclatlBanuine (Ph teB)u to the compound of Bo (cStage-VIItIB) D-Phe Cys-Phe-D-Trp-B Lo yc u s-Thr-Cys-T t hB ru -O-Resin formula C obtain compound of formula D (Stage-I F; Xm) oc-D-Phe-OH Resin D-Phe-Cys-PheB-Do-cTrBpo-cL TyFsAtB-Tuhr-Cys t-BTuhr-OL (S (tSatgaeg-eIX-X)) D-Phe-C Fyosr-mPhuela-D-Trp-Lys-Thr-Cys-Thr-OL T AFcAetic Acid d. deprotecting the heptapeptide of for (mStualgae D-X t)o obtain the Octreotide, e. isolating the O Dc-tPrehoeti-dCey fsr-oPmhe th-De r-eTsripn- aLnys-Thr-Cys-Thr-OL D-Phe-Cys-Phe-D-Trp-L Ayscde-T ftih lctre A-rCciniydgs t-oTh obr-tOaiLn. c Arucdeeta Otcetreotide, and (S (Stataggee-X-XI)) D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-OL. Acetate f. purifying and lyophilizing to o Obcttarieno Otidc Aetrc Aeeoctteiicdtae Atec Aidcetate. (Stage-XI) D-Phe-Cys-Phe- ODc-tTreropt-iLdeys A-cTehtar-tCeys-Thr-OL. Acetate (Stage-XI) Octreotide Acetate 8. The method as claimed in claim 1 and 7, wherein the Octreotide acetate is of 99.9% purity. 9. A peptide of formula E, Formula E
PCT/IB2024/060906 2024-01-25 2024-11-05 A method of preparation of octreotide acetate Pending WO2025158194A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202441005203 2024-01-25
IN202441005203 2024-01-25

Publications (1)

Publication Number Publication Date
WO2025158194A1 true WO2025158194A1 (en) 2025-07-31

Family

ID=96544711

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2024/060906 Pending WO2025158194A1 (en) 2024-01-25 2024-11-05 A method of preparation of octreotide acetate

Country Status (1)

Country Link
WO (1) WO2025158194A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8377891B2 (en) * 2008-11-07 2013-02-19 Usv, Ltd. Process for synthesis of cyclic octapeptide
US20140296144A1 (en) * 2011-09-30 2014-10-02 Mylan Laboratories, Ltd. Process for the preparation of octreotide acetate
WO2017175107A1 (en) * 2016-04-04 2017-10-12 Emcure Pharmaceuticals Limited Process for preparation of octreotide acetate

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8377891B2 (en) * 2008-11-07 2013-02-19 Usv, Ltd. Process for synthesis of cyclic octapeptide
US20140296144A1 (en) * 2011-09-30 2014-10-02 Mylan Laboratories, Ltd. Process for the preparation of octreotide acetate
WO2017175107A1 (en) * 2016-04-04 2017-10-12 Emcure Pharmaceuticals Limited Process for preparation of octreotide acetate

Similar Documents

Publication Publication Date Title
JP7315683B2 (en) Process for preparing GIP/GLP1 dual agonists
US4368192A (en) Peptides
JP2514518B2 (en) Somatostatin-like amide derivatives of heptapeptide and octapeptide, antitumor agent containing the same
KR20100036326A (en) Process for the production of pramlintide
CN111040020B (en) A kind of alkene thioether stapled peptide and its preparation method and application
JPS58146538A (en) Manufacture of n-monoacylated diem-diamino derivative
KR100341953B1 (en) Manufacturing method of azacyclohexapeptide
CN112585153B (en) A compound or its salt and its preparation method and application
CN110642936B (en) Method for preparing teriparatide
WO2005087794A1 (en) Process for octreotide synthesis
WO2025158194A1 (en) A method of preparation of octreotide acetate
CA2534224C (en) Preparation of somatostatin peptides
CN111378009A (en) Preparation method of octreotide
US5631230A (en) Receptor selective analogues of cholecystokinin-8
CN115368437A (en) A kind of method of solid-phase synthesis cyclic polypeptide
EP4504765A1 (en) Process for preparing a glp-1/glucagon dual agonist
WO2013046233A2 (en) Process for the preparation of octreotide acetate
CN119462826B (en) Pseudo peptide compound and preparation method and application thereof
CN111233980A (en) Method for synthesizing goserelin by fragment method
WO2013132505A1 (en) Improved process for preparation of octreotide by solution phase peptide synthesis
JP2026500375A (en) Process and intermediates for preparing tirzepatide
CN121378385A (en) Synthesis method of polypeptide compound containing two pairs of disulfide bonds
WO2020259714A1 (en) Method for preparing degarelix
CN120904313A (en) Tenipout Process for producing peptide
CN120699096A (en) A preparation method of eterkatide

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24920057

Country of ref document: EP

Kind code of ref document: A1